about
Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysisClinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic reviewComorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and ManagementComorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseaseAcute lung failureAbility of Reduced Lung Function to Predict Development of Atrial Fibrillation in Persons Aged 45 to 84 Years (from the Multi-Ethnic Study of Atherosclerosis-Lung Study)Smoking and smoking cessation in Latin America: a review of the current situation and available treatmentsThrombocytopenia: an early marker of late mortality in type B aortic dissection.Self-reported and actual beta-blocker prescribing for heart failure patients: physician predictors.The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settingsTension pneumothorax, is it a really life-threatening condition?Pneumocafé project: an inquiry on current COPD diagnosis and management among General Practitioners in Italy through a novel tool for professional education.Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD?Chronic obstructive pulmonary disease in older persons: A comparison of two spirometric definitionsRegular primary care lowers hospitalisation risk and mortality in seniors with chronic respiratory diseases.Elevated N-terminal pro-brain natriuretic peptide is associated with mortality in tobacco smokers independent of airflow obstruction.Circulating progenitor cells and vascular dysfunction in chronic obstructive pulmonary diseaseThe reliability of hospital and pharmaceutical data to assess prevalent cases of chronic obstructive pulmonary disease.Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study.The clinical value of serial measurement of high-sensitivity cardiac troponin T in acute exacerbations ofchronic obstructive pulmonary disease.Prevalence and risk factors of aortic aneurysm in patients with chronic obstructive pulmonary disease.A clinical in-hospital prognostic score for acute exacerbations of COPD.Lung function and risk for heart failure among older adults: the Health ABC Study.The ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary diseaseIs inflammatory chronic obstructive pulmonary disease a coronary heart disease risk equivalent? A longitudinal analysis of the third National Health and Nutrition Examination Survey (NHANES III), 1988-1994.Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor compositionImpact of cardiovascular comorbidities on COPD Assessment Test (CAT) and its responsiveness to pulmonary rehabilitation in patients with moderate to very severe COPD: protocol of the Chance study.Brief report: beta-blocker use among veterans with systolic heart failurePrognosis in patients having chronic obstructive pulmonary disease with significant coronary artery lesion anginaLung function, 25-hydroxyvitamin D concentrations and mortality in US adultsChemosensitivity, Cardiovascular Risk, and the Ventilatory Response to Exercise in COPD.Blood Pressure Profile and Hypertensive Organ Damage in COPD Patients and Matched Controls. The RETAPOC Study.Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010Prevalence, risk factors, activity limitation and health care utilization of an obese, population-based sample with chronic obstructive pulmonary disease.The relationship between pulmonary emphysema and kidney function in smokers.Prevalence of airflow obstruction in patients with stable systolic heart failure.The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study).NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study.Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: a cross-sectional study of the National Health and Nutrition Examination Survey from 2007-2010.
P2860
Q26781406-1130421E-5C5E-4C81-B6B9-243C9EC71E8DQ26782630-3775F6C3-BE2B-498F-89FC-DFAF0A16E8E9Q26799659-3DF5F45F-F01F-4974-8989-7167B522370CQ26823339-58C16630-5ADB-4C07-8192-9E5F8209D3DBQ26852173-8A1F1012-C84D-4EB6-AADC-17CC75A547A2Q28395242-EB587D7D-28FE-40F3-932B-9EAD489D76E5Q30371258-31DABB26-F442-470F-80CB-E57E653A207FQ33407180-4B6C2E94-66F3-4196-9E3F-350D168DACDAQ33521687-40ACB5ED-2BD9-45AD-9DD8-90E82374B62CQ33532293-D7C56A88-41DF-475E-8E85-D97FFBD8624AQ33592607-605CF435-1DAD-45D6-BB92-17848F503E12Q33770577-F46184BD-D201-48D1-81F3-B4735646C1ECQ33878940-3A9FF2E2-9239-470B-B6C6-F422DFD642D2Q33931328-72749F44-D311-4852-9D42-AD5B3F388DD2Q33959800-1EB94767-B742-49C3-B6B9-5FD24166CF0EQ34075676-7F201A67-340A-41D7-BB19-D20B89E0D5A5Q34110404-4D7DF645-142D-4670-B640-89BD5A46EB74Q34191666-464F4883-D530-412E-836A-76238C78A931Q34287954-AD175476-5ED6-4419-B371-CA4614B1047AQ34304730-77EBB9C7-9650-4145-9CFF-6BB36E9FC4C1Q34430477-A663F7D0-80C0-42FB-8E15-BCEF59AD8F8DQ34571705-B2746128-33CF-466D-BF12-275EADDF1447Q34777879-69C97052-B879-4488-94B2-A7BF3225170BQ35173527-C8725BA4-85DF-4C05-9555-C8A6C2739B9EQ35189528-1C02B695-C2CA-40EB-AA45-8EE76E7482C1Q35243446-6CBDDEC1-1C81-465D-9D3D-4D559FC69709Q35885017-08DED82C-62A3-4A15-A05E-1C50EC7A1D81Q35901592-F75C14E2-E8CC-43B7-86F5-C1DC42AE1F48Q36025242-8AB2DFCA-6770-4933-9FA6-2A12843324DDQ36061376-0CB7F431-53D0-46AD-A65F-B8300340739FQ36063861-EA0D72AA-5C88-4B3B-98C1-1B5E3531A754Q36064863-A7D355BB-810A-454C-8C69-F089E9E81F50Q36077372-A9D0C492-90A8-4402-AE68-A941FC2612D4Q36161117-169CD60A-B1FB-4F74-866C-9566A628C810Q36212650-B1230A00-1B44-4014-83D6-854284E40CC9Q36243275-E9D8B162-0DC3-43FA-8CEB-5E25A1DA544BQ36288980-6ECF4343-2038-4135-A2D7-067930E4AF1DQ36308003-ECF0E745-D873-4790-AC57-96A6586DC6D7Q36391975-7834B28D-5CCD-4A2B-BBC4-11C0CA24746AQ36539136-03C28D51-F2D7-4BC9-8315-CE2A7C6A1388
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cardiovascular morbidity and mortality in COPD.
@en
Cardiovascular morbidity and mortality in COPD.
@nl
type
label
Cardiovascular morbidity and mortality in COPD.
@en
Cardiovascular morbidity and mortality in COPD.
@nl
prefLabel
Cardiovascular morbidity and mortality in COPD.
@en
Cardiovascular morbidity and mortality in COPD.
@nl
P2093
P356
P1433
P1476
Cardiovascular morbidity and mortality in COPD.
@en
P2093
Laetitia Huiart
Pierre Ernst
Samy Suissa
P304
P356
10.1378/CHEST.128.4.2640
P407
P577
2005-10-01T00:00:00Z